Compare HOMB & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOMB | CRSP |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.2B |
| IPO Year | 2006 | 2016 |
| Metric | HOMB | CRSP |
|---|---|---|
| Price | $29.24 | $49.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 23 |
| Target Price | $33.00 | ★ $85.63 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 10-14-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 19.90 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | $4.24 | $1,052.09 |
| Revenue Next Year | $3.83 | $273.88 |
| P/E Ratio | $24.20 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $25.50 | $44.12 |
| 52 Week High | $31.70 | $75.06 |
| Indicator | HOMB | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 40.00 |
| Support Level | $29.09 | $45.61 |
| Resistance Level | $29.59 | $60.71 |
| Average True Range (ATR) | 0.52 | 2.58 |
| MACD | 0.10 | -0.51 |
| Stochastic Oscillator | 86.29 | 5.73 |
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.